在刚果民主共和国,Tecovirimat用于Clade I MPXV感染
, Rosine Ali1, Jules Alonga2
1Institut Nationale de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo.
The New England journal of medicine
|April 16, 2025
概括
在临床试验中,tecovirimat没有显著加快mopox (麻疹) 病变的愈合. 这种抗病毒药物在患有Clade I mpox.的患者中没有显示出安全问题.
科学领域:
- 病毒学 病毒学
- 传染性疾病 传染性疾病
- 临床试验 临床试验
背景情况:
- 根据动物研究和健康志愿者试验,Tecovirimat已被批准用于美国和欧洲的mpox (麻疹) 治疗.
- 从随机对照试验 (RCT) 获得的关于tecovirimat在mopox患者的安全性和有效性的强有力的临床证据以前缺乏.
研究的目的:
- 评估tecovirimat的疗效和安全性与安慰剂相比,在被诊断为因Clade I MPXV引起的mpox的患者中.
- 为了确定是否tecovirimat减少mopox病变的解决时间.
主要方法:
- 在刚果民主共和国进行了一项双盲,随机,安慰剂控制的试验.
- 597名具有mopox和阳性PCR结果的Clade I MPXV的患者被随机分配1:1接受tecovirimat或安慰剂,以及支持性护理.
- 主要终点是mopox病变消失的天数.
主要成果:
- 德科维里马特并没有显著减少病变消失的中位时间 (德科维里马特7天与安慰剂8天;P=0.14).
- 无论症状发病时间 (在7天内或7天后) 是否,疗效都相似.
- 总体死亡率为1.7%,低于刚果民主共和国2023年报告的4.6%病例死亡率. 两组之间没有观察到不良事件或严重不良事件的显著差异.
结论:
- 德科维里马在降低Clade I mpox患者的病变解决时间方面没有显示出统计学上显著的益处.
- 该研究没有发现与这个人群中使用tecovirimat相关的特定安全问题.
- 可能需要进一步的研究来探索tecovirimat在mopox管理中的作用,特别是在严重病例或不同类型中.
更多相关视频
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
15.6K
13:13Single-cell Quantitation of mRNA and Surface Protein Expression in Simian Immunodeficiency Virus-infected CD4+ T Cells Isolated from Rhesus macaques
Published on: September 25, 2018
10.6K
相关概念视频
01:28Antimicrobial Effectiveness
2.3K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
2.3K
01:29Subviral Agents
940
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
940
01:15Antifungal Agents
132
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
132
01:15Anthelminthic Agents
117
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
117